A cetaminophen (also known as APAP or paracetamol) has long been considered a safe nonprescription analgesic and antipyretic. Furthermore, it is considered a safe alternative to aspirin and other nonsteroidal anti-inflammatory agents (eg, naproxen sodium, ibuprofen, ketoprofen) for patients requiring anticoagulant therapy, children with fever (especially as pirin for children with possible viral infections because of the increased risk of Reye syndrome), and patients at risk for gastrointestinal ulceration and bleeding. The public is so comfortable with the safety of this drug that they do not routinely give attention to the warnings contained in the product labeling.
The risk of hepatotoxicity, ranging from changes in liver function blood tests to acute liver failure and death, is associated with acute overdose situations. It has been known for years that continuous use of higher amounts of acetaminophen is associated with hepatotoxicity as well. These cases of hepatotoxicity are not caused by the acetaminophen itself but rather by a toxic metabolite. The toxic metabolite binds with the liver proteins and causes cellular injury. 1, 2 The ability of the liver to remove the metabolite through conjugation influences the extent of the liver injury. 2 This ability is dependent on the amount of glutathione available for conjugating the toxic metabolite, which is decreased in patients who chronically ingest alcohol or in acute and chronic overdose situations. 2, 3 As a general rule, the maximum daily dose of acetaminophen should be no more than 4,000 mg per day to minimize the risk of chronic hepatotoxicity. However, many patients do not know how much acetaminophen they are actually taking on most days. If a patient takes 4 daily doses of 2 extra-strength nonprescription acetaminophen pills (500 mg/pill), the patient already has reached the maximum recommended dose. If this dosing regimen is combined with other nonprescription or prescription combination analgesic, cold, allergy, or sleep products that contain acetaminophen as an active ingredient (see Table 1), patients can quickly exceed the recommended daily dose and may not be aware that they have increased their risk for hepatotoxicity.
Although warnings regarding he patotoxicity have been strengthened over the years, intentional and unintentional overdoses oc cur continually because of lack of consumer awareness or concern. 1,4,5 In 2005 the Acute Liver Failure Study Group identified acetaminophen as the leading cause of acute liver failure in the United States, and 48% of these cases were associated with un -intentional overdose. 6 These warnings cannot be continually ignored, and action must be taken to protect consumers from this type of toxicity. The following measures can help decrease the risk of hepatotoxicity: increasing the public's awareness of the problem through an enhanced public education ef fort, improving labeling, eliminating combination products, decreasing the amount of acetaminophen per dosage unit, and lowering the maximum recommended doses. A report prepared by the US Food and Drug Administration's (FDA's) Aceta minophen Hepatotoxicity Work ing Group in February 2008 includes a number of these steps, as well as the following recommendations 7 , in creasing warnings regarding the risk of liver damage ad ded to acetaminophen-containing products, chang ing the maximum a mount of acetamin o phen per dosage unit from 500 to 325 mg, reducing the maximum recommended daily dose of acetaminophen to less than 4,000 mg, requiring a prescription for dosage units containing more than 325 mg, limiting the number of pills allowed in each container, and changing pediatric liquid formulations to 1 standardized strength. The FDA will make the final decision regarding which recommendations, if any, will be enacted. 8, 9 I believe that acetaminophen should not be removed from the market, but all or most of these recommendations should be implemented as soon as possible to decrease the risk of unintentional overdoses and to minimize the risk of hepatotoxicity. Health care professionals must pay close attention to their patients' total daily consump tion of acetaminophen from multiple sources, educate patients on the risk of acetaminophen-related hepatotoxicity, and help patients identify which of their prescription and nonprescription products contain acetaminophen. They also must educate patients to look closely at the labeling of any nonprescription product or ask their pharmacists to determine if a product contains acetaminophen before adding it to their drug regimens and to keep their total daily consumption of acetaminophen to 3,250 mg or less.
